BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 15784821)

  • 1. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a.
    Blumenfeld Z; Eckman A
    J Natl Cancer Inst Monogr; 2005; (34):40-3. PubMed ID: 15784821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
    Blumenfeld Z
    Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma.
    Blumenfeld Z; Avivi I; Eckman A; Epelbaum R; Rowe JM; Dann EJ
    Fertil Steril; 2008 Jan; 89(1):166-73. PubMed ID: 17601603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of gonadal damage during cytotoxic therapy.
    Blumenfeld Z; Haim N
    Ann Med; 1997 Jun; 29(3):199-206. PubMed ID: 9240625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian rescue/protection from chemotherapeutic agents.
    Blumenfeld Z
    J Soc Gynecol Investig; 2001; 8(1 Suppl Proceedings):S60-4. PubMed ID: 11223377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers.
    Blumenfeld Z
    Mol Cell Endocrinol; 2002 Feb; 187(1-2):93-105. PubMed ID: 11988316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data.
    Beck-Fruchter R; Weiss A; Shalev E
    Hum Reprod Update; 2008; 14(6):553-61. PubMed ID: 18820006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries.
    Blumenfeld Z
    Oncologist; 2007 Sep; 12(9):1044-54. PubMed ID: 17914074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation.
    Blumenfeld Z; Patel B; Leiba R; Zuckerman T
    Fertil Steril; 2012 Nov; 98(5):1266-70.e1. PubMed ID: 22935556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of ovarian function and fertility using a combination of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist during cancer treatment in young females.
    Potolog-Nahari C; Fishman A; Cohen I
    Gynecol Endocrinol; 2007 May; 23(5):290-4. PubMed ID: 17558688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GnRH-agonists in fertility preservation.
    Blumenfeld Z
    Curr Opin Endocrinol Diabetes Obes; 2008 Dec; 15(6):523-8. PubMed ID: 18971681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy.
    Blumenfeld Z; von Wolff M
    Hum Reprod Update; 2008; 14(6):543-52. PubMed ID: 18824495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy and fertility.
    Blumenfeld Z
    Best Pract Res Clin Obstet Gynaecol; 2012 Jun; 26(3):379-90. PubMed ID: 22281514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fertility after treatment for Hodgkin's disease.
    Blumenfeld Z; Dann E; Avivi I; Epelbaum R; Rowe JM
    Ann Oncol; 2002; 13 Suppl 1():138-47. PubMed ID: 12078896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
    Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M
    Lupus; 2000; 9(6):401-5. PubMed ID: 10981642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report.
    Pereyra Pacheco B; Méndez Ribas JM; Milone G; Fernández I; Kvicala R; Mila T; Di Noto A; Contreras Ortiz O; Pavlovsky S
    Gynecol Oncol; 2001 Jun; 81(3):391-7. PubMed ID: 11371127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases.
    Blumenfeld Z; Mischari O; Schultz N; Boulman N; Balbir-Gurman A
    Semin Arthritis Rheum; 2011 Dec; 41(3):346-52. PubMed ID: 21868068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Protective effect of GnRH analogues on the reproductive capacity of women with neoplasia or autoimmune disease who require chemotherapy. Final results of a phase ii clinical trial].
    Gris-Martínez JM; Trillo-Urrutia L; Gómez-Cabeza JJ; Encabo-Duró G
    Med Clin (Barc); 2016 Feb; 146(3):97-103. PubMed ID: 26194532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy.
    Castelo-Branco C; Nomdedeu B; Camus A; Mercadal S; Martínez de Osaba MJ; Balasch J
    Fertil Steril; 2007 Mar; 87(3):702-5. PubMed ID: 17173900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women.
    Blumenfeld Z; Avivi I; Ritter M; Rowe JM
    J Soc Gynecol Investig; 1999; 6(5):229-39. PubMed ID: 10554760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.